Search

Pharmaceutical Co-Operation Underway ICGEB and Sun Pharma to Develop novel botanical drug for treatment of Dengue

| Editor: Dominik Stephan

International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma have signed an agreement to develop a novel botanical drug for treatment of dengue.

Related Company

(Picture: Darko Stojanovic (CC0))

New Delhi/India – Through this agreement, Sun Pharma commits development of Cissampelos pariera (Cipa), a botanical drug in collaboration with ICGEB. Through this agreement Sun Pharma will follow up on earlier pre-clinical collaboration between ICGEB and erstwhile Ranbaxy Laboratories Ltd. Sun Pharma will develop Cipa, a botanical drug following a drug registration process similar to a new chemical entity, consisting of all required in-vitro, in-vivo, pre-clinical and clinical studies meeting all regulatory standards of India and other regulatory agencies worldwide.

According to Director International Centre for Genetic Engineering and Biotechnology, New Delhi, Dr Dinakar M Salunke, “Dengue, a mosquito-borne viral disease, poses a significant global public health risk. In tropical countries such as India where periodic dengue outbreaks can be correlated to the high prevalence of the mosquito vector, circulation of all four dengue viruses (DENVs) and the high population density, a drug for dengue is being increasingly recognized as an unmet public health need. Using the knowledge of traditional Indian medicine, we explored the indigenous herbal bio-resource to identify plants with pan-DENV inhibitory activity and identified CIPA as a safe, affordable and effective solution.”

(ID:44052451)